Taiwan Autoimmunity and inflammation companies and pipeline landscape (November 2026) | Drugnews
At least 4 Taiwanese biotech companies are active in Autoimmunity and inflammation, with 4 assets in development or on the market. The most advanced is HSHC (4194)’s IBD98-M (Phase 2; Colitis, Ulcerative). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
4 / 4
| HSHC (4194) | 4194 | IBD98-M | Not disclosed | Phase 2; completed | Colitis, Ulcerative | Not disclosed | No dated update | 2021-10-26 |
| TaiwanJ (6549) | 6549 | JKB-122 | Not disclosed | Phase 2; completed | Autoimmune Hepatitis | Not disclosed | No dated update | 2020-07-21 |
| PharmaEssentia (6446) | 6446 | KX01 | Not disclosed | Phase 1; completed | Psoriasis | Not disclosed | No dated update | 2025-07-02 |
| Pell Bio-Med (6949) | 6949 | PP011 | Not disclosed | Phase 1 trial in healthy participants authorized | Rheumatoid arthritis program; trial in healthy participants | Not disclosed | No dated update | 2026-06-02 2026-06-02 |
No matches. Clear the search to show all rows.
Recent events
- 未公開 Source
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing Autoimmunity and inflammation?
Currently, 4 companies are included: HSHC (4194), TaiwanJ (6549), PharmaEssentia (6446), Pell Bio-Med (6949). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to Autoimmunity and inflammation?
Taiwan-listed companies directly involved in Autoimmunity and inflammation R&D, manufacturing or licensing include: HSHC (4194), TaiwanJ (6549), PharmaEssentia (6446), Pell Bio-Med (6949). Compiled from public information; this is not investment advice.
Which Taiwanese Autoimmunity and inflammation program is most advanced?
HSHC (4194)’s IBD98-M is at Phase 2 (Colitis, Ulcerative).
What is the latest important development in Taiwan’s Autoimmunity and inflammation sector?
The latest record is 2026-06-02: Pell Bio-Med (6949) 代100%持有之子公司沛?(上海)醫藥科技有限公司公告，本 公司研發針對類風濕關節炎(RA)之口服新藥PP011，接獲中國國 家藥品監督管理局（NMPA）同意進行第一期健康受試者臨床試驗.
SourceHow often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.